Biomica operates in the biotechnology sector, focusing on advanced microbial and genomic profiling to facilitate precision medicine and therapeutic discovery. The company serves healthcare providers, pharmaceutical companies, and research institutions by offering high-resolution taxonomy analysis of microbial communities, profiling of patients' genomic information, and functional analysis of microbial genes, pathways, and metabolites. Biomica's proprietary PRISM platform integrates microbiome profiles with genomic and phenotypic host profiles to make clinically relevant predictions. The business model revolves around leveraging its computational solutions and virtual screening platforms to identify unique microbiome-based therapeutic entities, which are then developed through preclinical and clinical phases. Revenue is generated through partnerships, licensing agreements, and the commercialization of its therapeutic discoveries.

Keywords: microbial profiling, genomic analysis, precision medicine, therapeutic discovery, PRISM platform, metagenomics, microbiome, drug discovery, biotechnology, healthcare.